Nitrogen-containing tri-fused ring derivative and application thereof in medicine
By developing heterocyclic compounds as PI3Kα inhibitors, the dose limitation and toxicity problems of mutant PI3Kα targeted therapy in the prior art have been solved, and the selective inhibition and therapeutic effect of PI3Kα has been improved.
Patent Information
- Application Number
- CN202410617825.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-25
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing PI3Kα inhibitors have toxic limitations such as dose limitation, hyperglycemia and hyperinsulinemia when targeting mutant PI3Kα, making it difficult to develop selective inhibitors, especially the mutation location is far away from the active site, resulting in limited treatment efficiency.
A heterocyclic compound or a pharmaceutically acceptable salt thereof is developed as a PI3Kα inhibitor designed to effectively inhibit PI3Kα by specific chemical structures for the treatment of related diseases.
Selective inhibition of mutant PI3Kα was achieved, reducing the impact on wild-type PI3Kα, expanding the drug administration window, reducing the risk of hyperglycemia and hyperinsulinemia, and improving the therapeutic effect on cancer cells.
Smart Images

Figure CN118994111A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a compound described by general formula (I) or its stereoisomers, tautomers or pharmaceutically acceptable salts, intermediates and preparation methods thereof, and use of the compounds in preparing drugs for treating diseases related to PI3Kα activity or expression. Background Art
[0002] Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that, upon activation by growth factor receptors and integrins, regulates cell proliferation, survival, and migration. Up to 70% of breast cancers have some form of molecular mutation in the PI3K-AKT-mTOR pathway. Activating mutations in PIK3CA (encoding the p110α subunit of PI3K) are highly prevalent in breast cancer and solid tumor malignancies.
[0003] WT PI3Kα plays a central role in regulating the body's glucose homeostasis, and PBK inhibition in patients often leads to hyperglycemia and / or hyperinsulinemia (Busaidy NL, et al, Management of metabolic effects associated with anticancer agents targeting the PBK-Akt-mTOR pathway. J Clin Oncol 2012; 30: 2919-28). In the case of cancers with mutated PI3Kα, the development of selective inhibitors for mutant PI3Kα can effectively overcome the compensatory problems of insulin and / or glucose caused by WT PI3Kα inhibition, which can increase the drug administration window and selectively inhibit the pathological signals of mutant PI3Kα in cancer cells without affecting the host's own WT PI3Ka (Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PBK in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov. 2016 Oct; 6(10): 1090-1105).
[0004] Current PI3Kα inhibitor development focuses on the active or orthosteric site, with equal effects on wild-type and mutant PI3Kα. Its efficacy is limited by toxicity mediated by targeting WT PI3Kα, including dose limitations, hyperglycemia and / or hyperinsulinemia. Because PI3Kα mutations are located far from the active site, mutation-selective inhibitors have been difficult to obtain. Inhibitors targeting the second peripheral binding pocket near known mutations (e.g., H1047R) are expected to become targets for the development of new anticancer drugs. Summary of the invention
[0005] The purpose of the present invention is to provide a class of heterocyclic compounds or pharmaceutically acceptable salts thereof, which are applied to PI3Kα inhibitors. The compounds of the present invention can effectively inhibit PI3Kα and can be used to treat diseases such as tumors.
[0006] The present invention provides a compound of general formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof,
[0007]
[0008] In some embodiments, the general formula (I) is selected from the compounds represented by formula (Ia),
[0009]
[0010] In some embodiments, Z is selected from O, S;
[0011] In some embodiments, X1 is selected from N, CH, NH, NR x1 , CR x2 ;
[0012] In some embodiments, X2 is selected from CH, NH, NR x1 , CR x2 ;
[0013] In some embodiments, X3 is selected from C or N. When X3 is selected from C, X2 cannot be selected from CH or CR x2 ;
[0014] In some embodiments, X1 is selected from N, NH, NR x1 When X2 is selected from NH, NR x1 , X3 is selected from C or N;
[0015] In some embodiments, X3 is selected from N, X2 is selected from CH, CR x2 When X1 is selected from N, CH, NH, NR x1 , CR x2 ;
[0016] In some embodiments, Selected from represents a single bond or a double bond;
[0017] In some embodiments, Selected from
[0018] In some embodiments, W1, W2, W3, and W4 are each independently selected from a bond, O, S, N, NR w1 , CR w2 or CR w3 R w4 , provided that at most one of W1, W2, W3, and W4 is selected from a bond, and when one of them is selected from a bond and ring C is selected from an aromatic ring, the other three cannot be selected from CR at the same time w2 ;
[0019] In some embodiments, when C is selected from a 6-membered aromatic ring or a heteroaromatic ring, W1, W2, W3, and W4 are each independently selected from N or CR x2 , and at most three of W1, W2, W3, and W4 are selected from N;
[0020] In some embodiments, when C is selected from a 5-membered heteroaromatic ring, W1 is selected from a bond, and W2, W3, and W4 are each independently selected from O, S, N, NR w1 or CR w2 , and at least one of W2, W3, and W4 is selected from CR w2 ;
[0021] In some embodiments, when C is selected from a non-aromatic ring, W1, W2, W3, and W4 are each independently selected from a bond, O, S, NR w1 or CR w3 R w4 , and at most one of W1, W2, W3, and W4 is selected from a bond; in some embodiments, W1, W2, W3, and W4 are each independently selected from a bond or CR w3 R w4 , at most 2 of W1, W2, W3, and W4 are selected from bonds; in some embodiments, W1 is selected from bonds, and one or two of W2, W3, and W4 are selected from CR w3 R w4 , the remaining one or two items are selected from O, S, NR w1 ;
[0022] In some embodiments, Selected from
[0023] In some embodiments, W1, W2, W3, and W4 in C1 are each independently selected from a bond, O, S, NR w1 or CRw3 R w4 , and at most one of W1, W2, W3, and W4 is selected from a bond, and at most two are selected from O, S, or NR w1 ;
[0024] In some embodiments, W1, W2, W3, and W4 in C2 are each independently selected from N or CR w2 , and at most three of W1, W2, W3, and W4 are selected from N;
[0025] In some embodiments, W2, W3, and W4 in C3 are each independently selected from O, S, N, NR w1 or CR w2 , and at least one of W2, W3, and W4 is selected from O, S, N, NR w1 , at least one of the remaining two items is selected from CR w2 ;
[0026] In some embodiments, Selected from
[0027] In some embodiments, W2 and W3 in C4 are independently selected from O, S, NR w1 or CR w3 R w4 , and at least one of W2 and W3 is selected from O, S or NR w1 ;
[0028] In some embodiments, W1 and W4 in C5 are independently selected from O, S, NR w1 or CR w3 R w4 , and at least one of W1 and W4 is selected from O, S or NR w1 ;
[0029] In some embodiments, W3 in C6 is independently selected from O, S, NR w1 ;
[0030] In some embodiments, W2 and W4 in C7 are each independently selected from O, S, NR w1 or CR w3 R w4 , and at least one of W2 and W4 is selected from O, S or NR w1 ;
[0031] In some embodiments, Selected from
[0032] In some embodiments, R 1 Selected from -L 1-R 1a or -L 1 -R 1b ;
[0033] In some embodiments, L 1 Each independently selected from a bond, -C≡C-, -C 1-4 Alkylene-, -C(=O)-, -C 0-2 Alkylene-OC 0-2 Alkylene-, -C 0-2 Alkylene-SC 0-2 Alkylene-, -C 0-2 Alkylene-NR L1 -C 0-2 Alkylene-, the alkylene group is optionally substituted by 1 to 4 R k replaced by;
[0034] In some embodiments, L 1 Each independently selected from a bond, -C≡C-, -C 1-3 Alkylene-, -C(=O)-, wherein the alkylene is optionally substituted by 1 to 4 R k replace;
[0035] In some embodiments, L 1 Each independently selected from a bond, -C≡C-, methylene, ethylene, -C(=O)-, wherein the methylene and ethylene are optionally substituted by 1 to 3 R k replace;
[0036] In some embodiments, R 1 Selected from R 1a , R 1b or -C≡CR 1b ;
[0037] In some embodiments, R 1a Selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 alkyl)2, wherein the alkyl, alkenyl, alkynyl group is optionally substituted by 1 to 4 R k replaced by;
[0038] In some embodiments, R 1a Selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-4 Alkyl, -OC1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl)2, wherein the alkyl, alkenyl, alkynyl group is optionally substituted by 1 to 4 R k replaced by;
[0039] In some embodiments, R 1a is selected from H, deuterium, F, Cl, Br, I, OH, CN, NO2, NH2, COOH, CONH2, NHCH3, N(CH3)2 or optionally 1 to 3 R k substituted one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio;
[0040] In some embodiments, R 1b Selected from C 3-12 Carbocyclic group, 4 to 12 membered heterocyclic group, C 6-10 Aryl or 5 to 10 membered heteroaryl, wherein the carbocyclic group, heterocyclic group, aryl or heteroaryl is optionally substituted by 1 to 4 members selected from R k replaced by;
[0041] In some embodiments, R 1b is selected from 4-7 membered heteromonocyclic group, 5-12 membered heterocyclic group, 5-12 membered heterospirocyclic group, 7-10 membered heterobridged ring group, C 3-8 Monocarbocyclic group, C 6-12 Cycloalkyl, C 6-12 Spirocycloalkyl, C 5-12 Benzene-C-cycloalkyl 3-6 Carbocyclic group, benzo 3 to 6 membered heterocyclic group, C 6-10 aryl or 5 to 10 membered heteroaryl, wherein R 1b 1 to 4 selected from R k replaced by;
[0042] In some embodiments, R 1b Selected from 1 to 3 R ksubstituted by one of the following groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolane, 1,4-dioxolane, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, thienyl, thiazolyl, furanyl, oxazolyl, isoxazolyl, benzopyrrole, benzothiophene, benzofuran, benzothiazole, benzopyrazole, benzimidazole, quinoline, isoquinoline, pyridopyridine, pyridothiazole, pyridofuran, pyridopyrrole,
[0043] In some embodiments, R x1 , R y1 , R w1 , R L1 Each independently selected from H, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -C 0-4 Alkylene-C 3-10 Carbocyclic group, -C 0-4 Alkylene-4 to 10 membered heterocyclic group, wherein the alkyl, alkenyl, alkynyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0044] In some embodiments, R x1 , R y1 , R w1 , R L1 Each independently selected from H, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -C 0-2 Alkylene-C 3-8 Carbocyclic group, -C 0-2 Alkylene-4 to 8 membered heterocyclic group, wherein the alkyl, alkenyl, alkynyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0045] In some embodiments, R x1 , R y1 , R w1 Each independently selected from H, deuterium or optionally substituted by 1 to 4 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, -CH2-cyclopropyl or -CH2-cyclobutyl;
[0046] In some embodiments, R L1 is selected from H, deuterium, methyl, ethyl;
[0047] In some embodiments, R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -C 0-4 Alkylene-C 3-12 Carbocyclic group, -C 0-4 Alkylene-4 to 12-membered heterocyclic group, -C 0-4 Alkylene-C(=O)C 1-6 Alkyl, -C 0-4 Alkylene-C(=O)OC 1-6 Alkyl, -C(=O)-C 3-12 carbocyclic group, -C(=O)-4 to 12 membered heterocyclic group, -C(=O)-CH2-C 3-12 Carbocyclic group, -C(=O)-CH2-4 to 12-membered heterocyclic group, -C(=O)NHC 1-6 Alkyl, -C(=O)N(C 1-6 Alkyl)2, -P(=O)(C 1-6 Alkyl)2, -S(=O) 1-2 C 1-6 Alkyl, -S(=O) 1-2 NHC 1-6 Alkyl, -S(=O) 1-2 N(C 1-6 Alkyl)2, -OC 0-4 Alkylene-C 3-12 Carbocyclic group, -OC 0-4 Alkylene-4 to 12-membered heterocyclic group, -SC 0-4 Alkylene-C 3-12 Carbocyclic group, -SC 0-4 Alkylene-4 to 12-membered heterocyclic group, -NHC 0-4 Alkylene-C 3-12 Carbocyclic group, -NHC 0-4 Alkylene-4 to 12 membered heterocyclic group, wherein the CH2, alkyl, alkylene, alkenyl, alkynyl, alkoxy, carbocyclic group, heterocyclic group is optionally substituted by 1 to 4 Rk replaced by;
[0048] In some embodiments, R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -C 0-2 Alkylene-C 3-8 Carbocyclic group, -C 0-2 Alkylene-4 to 7 membered heterocyclic group, -C 0-2 Alkylene-C(=O)C 1-4 Alkyl, -C 0-2 Alkylene-C(=O)OC 1-4 Alkyl, -C(=O)-C 3-8 carbocyclic group, -C(=O)-4 to 7 membered heterocyclic group, -C(=O)-CH2-C 3-8 Carbocyclic group, -C(=O)-CH2-4 to 7 membered heterocyclic group, -C(=O)NHC 1-4 Alkyl, -C(=O)N(C 1-4 Alkyl)2, -P(=O)(C 1-4 Alkyl)2, -S(=O) 1-2 C 1-4 Alkyl, -S(=O) 1-2 NHC 1-4 Alkyl, -S(=O) 1-2 N(C 1-4 Alkyl)2, -OC 0-2 Alkylene-C 3-8 Carbocyclic group, -OC 0-2 Alkylene-4 to 7 membered heterocyclic group, -SC 0-2 Alkylene-C 3-8 Carbocyclic group, -SC 0-2 Alkylene-4 to 7 membered heterocyclic group, -NHC 0-2 Alkylene-C 3-8 Carbocyclic group, -NHC 0-2 Alkylene-4 to 7 membered heterocyclic group, wherein the CH2, alkyl, alkylene, alkenyl, alkynyl, alkoxy, carbocyclic group, heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0049] In some embodiments, R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, NHCH3, N(CH3)2, COOH, CONH2 or optionally substituted by 1 to 4 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-pyrrolidinyl, -O-cyclopropyl, -O-cyclobutyl, -O-pyrrolidinyl, -S-cyclopropyl, -S-cyclobutyl, -NH-cyclopropyl, -NH-cyclobutyl, -OCH2-cyclopropyl, imidazole, pyrazole, pyrrole or thiophene;
[0050] In some embodiments, R x2 is selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NO2, NHCH3, N(CH3)2, COOH, CONH2 or optionally 1 to 3 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-pyrrolidinyl;
[0051] In some embodiments, Y is selected from O, S, NR y1 ;
[0052] In some embodiments, Y is selected from O, S, NH;
[0053] In some embodiments, Selected from
[0054] In some embodiments, m is selected from 1, 2, 3, 4;
[0055] In some embodiments, m is selected from 1, 2;
[0056] In some embodiments, m is selected from 1;
[0057] In some embodiments, in certain embodiments, Ring B is selected from C 3-14Carbocyclic group, 4 to 14 membered heterocyclic group, C 6-10 Aryl or 5 to 10 membered heteroaryl, wherein the carbocyclic group, heterocyclic group, aryl or heteroaryl is optionally substituted by 1 to 5 members selected from R b replaced by;
[0058] In some embodiments, each of the rings B is independently selected from a 4-7 membered heteromonocyclic ring, a 5-12 membered heterocyclic ring, a 5-12 membered heterospirocyclic ring, a 7-10 membered heterobridged ring, a C 3-8 Monocarbocyclic group, C 6-12 Cycloalkyl, C 6-12 Spirocycloalkyl, C 5-12 Benzene-C-cycloalkyl 3-8 Carbocyclic group, benzo 3 to 8 membered heterocyclic group, C 6-10 aryl, 5-10 membered heteroaryl, the ring B is optionally substituted by 1 to 4 R b replaced by;
[0059] In some embodiments, each Ring B is independently selected from C 6-10 aryl, 5-10 membered heteroaryl, the ring B is optionally substituted by 1 to 4 R b replaced by;
[0060] In some embodiments, Ring B is selected from b One of the following substituted groups: phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl;
[0061] In some embodiments, Selected from
[0062] In some embodiments, Selected from
[0063] In some embodiments, Selected from
[0064] In some embodiments, Selected from
[0065] In some embodiments, B1, B2, B3, B4, B6 are each independently selected from N or CR b , at most three of B1, B2, B3, B4, B6 are selected from N;
[0066] In some embodiments, B1, B2, B3, and B6 are each independently selected from N or CR b , at most two of B1, B2, B3, B6 are selected from N;
[0067] In some embodiments, three of B1, B2, B3, and B6 are selected from CR b , and the remaining one is selected from N; in some embodiments, B2 and B3 are each independently selected from N or CR b ;
[0068] In some embodiments, Selected from
[0069] In some embodiments, R 5 , R 6 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 0-4 Alkylene-5 to 10 membered heteroaryl, C 0-4 Alkylene-C 3-10 Carbocyclic group, C 0-4 Alkylene-4 to 10 membered heterocyclic group, wherein the alkyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0070] In some embodiments, R 5 , R 6 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 0-2 Alkylene-5 to 8 membered heteroaryl, C 0-2 Alkylene-C 3-8 Carbocyclic group, C 0-2 Alkylene-4 to 8 membered heterocyclic group, wherein the alkyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0071] In some embodiments, R 5 , R 6 Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NO2, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R ksubstituted by one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl;
[0072] In some embodiments, R 5 , R 6 and the carbon atom to which it is attached directly to form C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl or 3 to 7 membered heterocyclic ring, wherein the cycloalkyl, cycloalkenyl or heterocyclic ring is optionally substituted by 1 to 4 R k replace;
[0073] In some embodiments, R 5 , R 6 Directly connect with the carbon atom to which it is attached to form cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
[0074] In some embodiments, R k Each independently selected from deuterium, halogen, =O, CN, OH, NO2, COOH, CONH2, NH2, SF5, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -C 1-4 Alkylene-C 3-6 Carbon ring, -C 1-4 Alkylene-3 to 7 membered heterocyclic ring, C 3-6 carbocyclic ring, 3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 atoms selected from deuterium, halogen, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;
[0075] In some embodiments, R k Each independently selected from deuterium, halogen, =O, CN, OH, NO2, COOH, CONH2, NH2, SF5, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4Alkyl, -SC 1-4 Alkyl, -OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -C 1-2 Alkylene-C 3-6 Carbon ring, -C 1-2 Alkylene-3 to 7 membered heterocyclic ring, C 3-6 carbocyclic ring, 3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 atoms selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0076] In some embodiments, R k Each independently selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, NO2, SF5, COOH, CONH2, NH(CH3), NH(CH2CH3), N(CH3)2, N(CH2CH3)2, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0077] In some embodiments, R k Each is independently selected from deuterium, F, Cl, Br, I, OH, =O, COOH, CN, SF5, CHF2, CH2F, CF3, OCHF2, OCF3, CD3, OCD3, NH2, NHCH3, N(CH3)2, CH2OH, OCH2OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, and morpholinyl.
[0078] As a first embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0079] represents an aromatic ring or a non-aromatic ring;
[0080] Z is selected from O and S;
[0081] X1 is selected from N, CH, NH, NR x1 , CR x2 ;
[0082] X2 is selected from CH, NH, NR x1 , CR x2 ;
[0083] X3 is selected from C or N. When X3 is selected from C, X2 cannot be selected from CH or CR x2 ;
[0084] W1, W2, W3, and W4 are each independently selected from a bond, O, S, N, NR w1 , CR w2 or CR w3 R w4 , provided that at most one of W1, W2, W3, and W4 is selected from a bond, and when one of them is selected from a bond and ring C is selected from an aromatic ring, the other three cannot be selected from CR at the same time w2 ;
[0085] Y is selected from O, S, NR y1 ;
[0086] R 1 Selected from -L 1 -R 1a or -L 1 -R 1b ;
[0087] m is selected from 1, 2, 3, 4;
[0088] L 1 Each independently selected from a bond, -C≡C-, -C 1-4 Alkylene-, -C(=O)-, -C 0-2 Alkylene-OC 0-2 Alkylene-, -C 0-2 Alkylene-SC 0-2 Alkylene-, -C 0-2 Alkylene-NR L1 -C 0-2 Alkylene-, the alkylene group is optionally substituted by 1 to 4 R k replaced by;
[0089] R 1a Selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C1-6 alkyl)2, wherein the alkyl, alkenyl, alkynyl group is optionally substituted by 1 to 4 R k replaced by;
[0090] R 1b Selected from C 3-12 Carbocyclic group, 4 to 12 membered heterocyclic group, C 6-10 Aryl or 5 to 10 membered heteroaryl, wherein the carbocyclic group, heterocyclic group, aryl or heteroaryl is optionally substituted by 1 to 4 members selected from R k replaced by;
[0091] Ring B is selected from C 3-14 Carbocyclic group, 4 to 14 membered heterocyclic group, C 6-10 Aryl or 5 to 10 membered heteroaryl, wherein the carbocyclic group, heterocyclic group, aryl or heteroaryl is optionally substituted by 1 to 5 members selected from R b replaced by;
[0092] R x1 , R y1 , R w1 , R L1 Each independently selected from H, deuterium, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -C 0-4 Alkylene-C 3-10 Carbocyclic group, -C 0-4 Alkylene-4 to 10 membered heterocyclic group, wherein the alkyl, alkenyl, alkynyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0093] R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -C 0-4 Alkylene-C 3-12 Carbocyclic group, -C 0-4 Alkylene-4 to 12-membered heterocyclic group, -C 0-4 Alkylene-C(=O)C 1-6 Alkyl, -C 0-4 Alkylene-C(=O)OC1-6 Alkyl, -C(=O)-C 3-12 carbocyclic group, -C(=O)-4 to 12 membered heterocyclic group, -C(=O)-CH2-C 3-12 Carbocyclic group, -C(=O)-CH2-4 to 12-membered heterocyclic group, -C(=O)NHC 1-6 Alkyl, -C(=O)N(C 1-6 Alkyl)2, -P(=O)(C 1-6 Alkyl)2, -S(=O) 1-2 C 1-6 Alkyl, -S(=O) 1-2 NHC 1-6 Alkyl, -S(=O) 1-2 N(C 1-6 Alkyl)2, -OC 0-4 Alkylene-C 3-12 Carbocyclic group, -OC 0-4 Alkylene-4 to 12-membered heterocyclic group, -SC 0-4 Alkylene-C 3-12 Carbocyclic group, -SC 0-4 Alkylene-4 to 12-membered heterocyclic group, -NHC 0-4 Alkylene-C 3-12 Carbocyclic group, -NHC 0-4 Alkylene-4 to 12 membered heterocyclic group, wherein the CH2, alkyl, alkylene, alkenyl, alkynyl, alkoxy, carbocyclic group, heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0094] R 5 , R 6 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 0-4 Alkylene-5 to 10 membered heteroaryl, C 0-4 Alkylene-C 3-10 Carbocyclic group, C 0-4 Alkylene-4 to 10 membered heterocyclic group, wherein the alkyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0095] Alternatively, R 5 , R 6 and the carbon atom to which it is attached directly to form C 3-6 Cycloalkyl, C3-6 Cycloalkenyl or 3 to 7 membered heterocyclic ring, wherein the cycloalkyl, cycloalkenyl or heterocyclic ring is optionally substituted by 1 to 4 R k replace;
[0096] R k Each independently selected from deuterium, halogen, =O, CN, OH, NO2, COOH, CONH2, NH2, SF5, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -C 1-4 Alkylene-C 3-6 Carbon ring, -C 1-4 Alkylene-3 to 7 membered heterocyclic ring, C 3-6 carbocyclic ring, 3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 atoms selected from deuterium, halogen, CN, OH, NH2, C 1-6 Alkyl, C 1-6 The alkoxy group is substituted with an alkoxy substituent.
[0097] As a second embodiment of the present invention, the compound represented by the following general formula (I) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0098] R 1a Selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl)2, wherein the alkyl, alkenyl, alkynyl group is optionally substituted by 1 to 4 R k replaced by;
[0099] R 1b is selected from 4-7 membered heteromonocyclic group, 5-12 membered heterocyclic group, 5-12 membered heterospirocyclic group, 7-10 membered heterobridged ring group, C 3-8 Monocarbocyclic group, C 6-12 Cycloalkyl, C 6-12 Spirocycloalkyl, C 5-12 Benzene-C-cycloalkyl 3-6Carbocyclic group, benzo 3 to 6 membered heterocyclic group, C 6-10 aryl or 5 to 10 membered heteroaryl, wherein R 1b 1 to 4 selected from R k replaced by;
[0100] R x1 , R y1 , R w1 , R L1 Each independently selected from H, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -C 0-2 Alkylene-C 3-8 Carbocyclic group, -C 0-2 Alkylene-4 to 8 membered heterocyclic group, wherein the alkyl, alkenyl, alkynyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0101] Selected from
[0102] Ring B is selected from 4-7 membered heteromonocyclic group, 5-12 membered heterocyclic group, 5-12 membered heterospirocyclic group, 7-10 membered heterobridged ring group, C 3-8 Monocarbocyclic group, C 6-12 Cycloalkyl, C 6-12 Spirocycloalkyl, C 5-12 Benzene-C-cycloalkyl 3-6 Carbocyclic group, benzo 3 to 6 membered heterocyclic group, C 6-10 aryl or 5 to 10 membered heteroaryl, the ring B is optionally substituted by 1 to 4 R b replaced by;
[0103] R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, COOH, CONH2, C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -C 0-2 Alkylene-C 3-8 Carbocyclic group, -C 0-2 Alkylene-4 to 7 membered heterocyclic group, -C 0-2Alkylene-C(=O)C 1-4 Alkyl, -C 0-2 Alkylene-C(=O)OC 1-4 Alkyl, -C(=O)-C 3-8 carbocyclic group, -C(=O)-4 to 7 membered heterocyclic group, -C(=O)-CH2-C 3-8 Carbocyclic group, -C(=O)-CH2-4 to 7 membered heterocyclic group, -C(=O)NHC 1-4 Alkyl, -C(=O)N(C 1-4 Alkyl)2, -P(=O)(C 1-4 Alkyl)2, -S(=O) 1- 2C 1-4 Alkyl, -S(=O) 1-2 NHC 1-4 Alkyl, -S(=O) 1-2 N(C 1-4 Alkyl)2, -OC 0-2 Alkylene-C 3-8 Carbocyclic group, -OC 0-2 Alkylene-4 to 7 membered heterocyclic group, -SC 0-2 Alkylene-C 3-8 Carbocyclic group, -SC 0-2 Alkylene-4 to 7 membered heterocyclic group, -NHC 0-2 Alkylene-C 3-8 Carbocyclic group, -NHC 0-2 Alkylene-4 to 7 membered heterocyclic group, wherein the CH2, alkyl, alkylene, alkenyl, alkynyl, alkoxy, carbocyclic group, heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0104] R 5 , R 6 Each independently selected from H, deuterium, halogen, OH, CN, NO2, NH2, C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 0-2 Alkylene-5 to 8 membered heteroaryl, C 0-2 Alkylene-C 3-8 Carbocyclic group, C 0-2 Alkylene-4 to 8 membered heterocyclic group, wherein the alkyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by;
[0105] The remaining definitions are the same as those of the first embodiment of the present invention.
[0106] As a third embodiment of the present invention, the compound represented by the aforementioned general formula (I) or (Ia) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0107] L 1 Each independently selected from a bond, -C≡C-, -C 1-3 Alkylene-, -C(=O)-, wherein the alkylene is optionally substituted by 1 to 4 R k replace;
[0108] When C is selected from a 6-membered aromatic ring or a heteroaromatic ring, W1, W2, W3, and W4 are each independently selected from N or CR x2 , and at most three of W1, W2, W3, and W4 are selected from N;
[0109] When C is selected from a 5-membered heteroaromatic ring, W1 is selected from a bond, and W2, W3, and W4 are each independently selected from O, S, N, NR w1 or CR w2 , and at least one of W2, W3, and W4 is selected from CR w2 ;
[0110] When C is selected from a non-aromatic ring, W1, W2, W3, and W4 are each independently selected from a bond, O, S, NR w1 or CR w3 R w4 , and at most one of W1, W2, W3, and W4 is selected from a bond;
[0111] R k Each independently selected from deuterium, halogen, =O, CN, OH, NO2, COOH, CONH2, NH2, SF5, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -C 1-2 Alkylene-C 3-6 Carbon ring, -C 1-2 Alkylene-3 to 7 membered heterocyclic ring, C 3-6 carbocyclic ring, 3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 atoms selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0112] The remaining definitions are the same as those of the first or second embodiment of the present invention.
[0113] As a fourth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or (Ia) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0114] R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, NHCH3, N(CH3)2, COOH, CONH2 or optionally substituted by 1 to 4 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-pyrrolidinyl, -O-cyclopropyl, -O-cyclobutyl, -O-pyrrolidinyl, -S-cyclopropyl, -S-cyclobutyl, -NH-cyclopropyl, -NH-cyclobutyl, -OCH2-cyclopropyl, imidazole, pyrazole, pyrrole or thiophene;
[0115] R x1 , R y1 , R w1 Each independently selected from H, deuterium or optionally substituted by 1 to 4 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, -CH2-cyclopropyl or -CH2-cyclobutyl;
[0116] Ring B is selected from b One of the following substituted groups: phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl;
[0117] R 5 , R 6 Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NO2, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R ksubstituted by one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl;
[0118] Selected from
[0119] Selected from
[0120] represents a single bond or a double bond;
[0121] In C1, W1, W2, W3, and W4 are each independently selected from a bond, O, S, NR w1 or CR w3 R w4 , and at most one of W1, W2, W3, and W4 is selected from a bond, and at most two are selected from O, S, or NR w1 ;
[0122] In C2, W1, W2, W3, and W4 are each independently selected from N or CR w2 , and at most three of W1, W2, W3, and W4 are selected from N;
[0123] In C3, W2, W3, and W4 are each independently selected from O, S, N, NR w1 or CR w2 , and at least one of W2, W3, and W4 is selected from O, S, N, NR w1 , at least one of the remaining two items is selected from CR w2 ;
[0124] R k Each independently selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, NO2, SF5, COOH, CONH2, NH(CH3), NH(CH2CH3), N(CH3)2, N(CH2CH3)2, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0125] The remaining definitions are the same as those of the first, second or third embodiment of the present invention.
[0126] As a fifth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or (Ia) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0127] Selected from
[0128] L 1 Each independently selected from a bond, -C≡C-, methylene, ethylene, -C(=O)-, wherein the methylene and ethylene are optionally substituted by 1 to 3 R k replace;
[0129] In C4, W2 and W3 are independently selected from O, S, NR w1 or CR w3 R w4 , and at least one of W2 and W3 is selected from O, S or NR w1 ;
[0130] In C5, W1 and W4 are independently selected from O, S, NR w1 or CR w3 R w4 , and at least one of W1 and W4 is selected from O, S or NR w1 ;
[0131] In C6, W3 are each independently selected from O, S, NR w1 ;
[0132] In C7, W2 and W4 are independently selected from O, S, NR w1 or CR w3 R w4 , and at least one of W2 and W4 is selected from O, S or NR w1 ;
[0133] Y is selected from O, S, NH;
[0134] R 1a is selected from H, deuterium, F, Cl, Br, I, OH, CN, NO2, NH2, COOH, CONH2, NHCH3, N(CH3)2 or optionally 1 to 3 R k substituted one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio;
[0135] R 1b Selected from 1 to 3 R ksubstituted by one of the following groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolane, 1,4-dioxolane, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, thienyl, thiazolyl, furanyl, oxazolyl, isoxazolyl, benzopyrrole, benzothiophene, benzofuran, benzothiazole, benzopyrazole, benzimidazole, quinoline, isoquinoline, pyridopyridine, pyridothiazole, pyridofuran, pyridopyrrole,
[0136] m is selected from 1;
[0137] The remaining definitions are the same as those of the first, second, third or fourth embodiment of the present invention.
[0138] As a sixth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or (Ia) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0139] Selected from
[0140] R 1 Selected from R 1a , R 1b or -C≡CR 1b ;
[0141] R x2 is selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NO2, NHCH3, N(CH3)2, COOH, CONH2 or optionally 1 to 3 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-pyrrolidinyl;
[0142] R k Each independently selected from deuterium, F, Cl, Br, I, OH, =O, COOH, CN, SF5, CHF2, CH2F, CF3, OCHF2, OCF3, CD3, OCD3, NH2, NHCH3, N(CH3)2, CH2OH, OCH2OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl;
[0143] Selected from
[0144] The remaining definitions are the same as those of the first, second, third, fourth or fifth embodiment of the present invention.
[0145] As a seventh embodiment of the present invention, the compound represented by the aforementioned general formula (Ia) or its stereoisomer, tautomer or pharmaceutically acceptable salt,
[0146] R 1b Selected from 1 to 3 R k substituted by one of the following groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolane, 1,4-dioxolane, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, thienyl, thiazolyl, furanyl, oxazolyl, isoxazolyl, benzopyrrole, benzothiophene, benzofuran, benzothiazole, benzopyrazole, benzimidazole, quinoline, isoquinoline, pyridopyridine, pyridothiazole, pyridofuran, pyridopyrrole,
[0147] Preferably, 1, 2 or 3 R k One of the following groups substituted:
[0148] R x1 is selected from H, deuterium, F, Cl or optionally 1 to 3 R k Substituted one of the following groups: methyl, ethyl, propyl, isopropyl;
[0149] B2 and B3 are each independently selected from N or CR b ;
[0150] R b Each independently selected from H, deuterium, F, Cl, OH, CN, NH2, NO2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k Substituted one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy;
[0151] R 5 , R 6 Each independently selected from H, deuterium, F, Cl, Br or optionally substituted by 1 to 3 R k Substituted one of the following groups: methyl, ethyl.
[0152] The present invention relates to the compounds shown below or their stereoisomers, tautomers or pharmaceutically acceptable salts, wherein the compound is selected from one of the structures shown in Table E-1.
[0153] The present invention relates to a pharmaceutical composition, comprising any of the above compounds or their stereoisomers, tautomers or pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier.
[0154] The present invention relates to a pharmaceutical composition, comprising a therapeutically effective amount of the above-mentioned compound of the present invention or its stereoisomer, tautomer or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.
[0155] In some embodiments, the pharmaceutical composition of the present invention may be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as "preparation strength").
[0156] The "effective amount" or "therapeutically effective amount" described in this application refers to the administration of a sufficient amount of the compound disclosed in this application, which will alleviate one or more symptoms of the disease or condition being treated (e.g., PI3Kα abnormality-related diseases such as cancer) to some extent. In some embodiments, the result is to reduce and / or alleviate the signs, symptoms or causes of the disease, or any other desired changes in the biological system. For example, an "effective amount" for therapeutic use is the amount of the compound disclosed in this application required to provide a clinically significant reduction in disease symptoms.Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40-600 mg, 50-600 mg, 60-600 mg, 70-600 mg, 75-600 mg, 80-600 mg, 90-600 mg, 100-600 mg, 200-600 mg, 1-500 mg, 2-500mg, 3-500mg, 4-500mg, 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-500mg, 50-500mg, 60-500mg, 70-500mg, 75-500mg , 80-500mg, 90-500mg, 100-500mg, 125-500mg, 150-500mg, 200-500mg, 250-500mg, 300-500mg, 400-500mg, 5-400mg, 10-400mg, 20-400mg, 25-40 0mg, 30-400mg, 40-400mg, 50-400mg, 60-400mg, 70-400mg, 75-400mg, 80-400mg, 90-400mg, 100-400mg, 125-400mg, 150-400mg, 200-400mg, 250- 400mg, 300-400mg, 1-300mg, 2-300mg, 5-300mg, 10-300mg, 20-300mg, 25-300mg, 30-300mg, 40-300mg, 50-300mg, 60-300mg, 70-300mg, 75-300mg , 80-300mg, 90-300mg, 100-300mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200mg, 25-200mg, 30-200mg, 40-200mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg, 80-1000mg, 80-800mg.
[0157] In some embodiments, the pharmaceutical composition includes but is not limited to 1-1000 mg, 20-800 mg, 40-800 mg, 40-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg g, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg, 320 mg, 400 mg, 480 mg, 500 mg, 600 mg, 640 mg, 840 mg of a compound of the present invention or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
[0158] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, the therapeutically effective amount preferably being 1-1500 mg, and the disease preferably being a disease related to PI3Kα activity or expression (such as cancer).
[0159] A method for treating a disease in a mammal, the method comprising administering a drug compound of the present invention or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof to a subject at a daily dose of 1-1000 mg / day, the daily dose may be a single dose or divided doses, in some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day, 25-400 In some embodiments, the daily dose includes but is not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 80 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 160 mg / day, 200 mg / day, 300 mg / day, 320 mg / day, 400 mg / day, 480 mg / day, 600 mg / day, 640 mg / day, 800 mg / day, 1000 mg / day.
[0160] The present invention relates to a kit, which may include a composition in a single-dose or multi-dose form, and the kit contains a compound of the present invention or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, and the amount of the compound of the present invention or its stereoisomer, tautomer or pharmaceutically acceptable salt is the same as that in the above-mentioned pharmaceutical composition.
[0161] The present invention relates to the use of any of the above-mentioned compounds or their stereoisomers, tautomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating diseases related to PI3Kα activity or expression, preferably, the disease is selected from tumors, preferably breast cancer.
[0162] The present invention relates to the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating a disease associated with PI3Kα activity or expression. Preferably, the disease is selected from tumors, preferably breast cancer.
[0163] The amount of the compound according to the invention or of a stereoisomer, tautomer or pharmaceutically acceptable salt thereof is in each case calculated as the free base.
[0164] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0165] The compounds of the present invention also include deuterated forms, solvates, prodrugs, metabolites or co-crystals.
[0166] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally further replaced by one or more of their corresponding isotopes, wherein the carbon isotopes include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, isotopes of nitrogen include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, isotopes of chlorine include 35 Cl and 37 Isotopes of Cl and bromine include79 Br and 81 Br.
[0167] "CN" refers to cyano.
[0168] "Halogen" refers to F, Cl, Br or I.
[0169] "Halogen substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, and substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen substituted" is abbreviated as "halo".
[0170] "Alkyl" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; alkyl groups can be monovalent, divalent, trivalent, or tetravalent.
[0171] "Heteroalkyl" refers to a substituted or unsubstituted alkyl group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X-(CH2)vX-(CH2)vX-(CH2)vH (v is an integer from 1 to 5, each X is independently selected from a bond or a heteroatom, the heteroatom includes but is not limited to N, O or S, and at least one X is selected from a heteroatom, and the N or S in the heteroatom can be oxidized to various oxidation states). The heteroalkyl group can be monovalent, divalent, trivalent or tetravalent.
[0172] "Alkylene" refers to substituted or unsubstituted straight-chain or branched divalent saturated hydrocarbon groups, including -(CH2) v -(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.
[0173] "Heteroalkylene" refers to a substituted or unsubstituted alkylene in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X-(CH2)vX-(CH2)vX-(CH2)v-, v is an integer from 1 to 5, each X is independently selected from a bond, N, O or S, and at least one X is selected from N, O or S.
[0174] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 12 carbon atoms, and the cycloalkyl radical can be a monocyclic, cyclic, bridged, and spirocyclic ring. Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutyl-cyclobutyl, cyclobutyl-spirocyclobutyl, adamantane, etc. The cycloalkyl radical can be monovalent, divalent, trivalent, or tetravalent.
[0175] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon containing heteroatoms, including but not limited to 3 to 12 atoms, 3 to 8 atoms, including 1 to 3 heteroatoms selected from N, O, S or Se, and the C, N, S on the ring of the heterocycloalkyl can be oxidized to various oxidation states. Heterocycloalkyl can be a monocyclic, cyclic, bridged and spirocyclic. Heterocycloalkyl can be connected to a heteroatom or a carbon atom, and non-limiting examples include oxirane, aziridine, oxadiazine, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolane, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazininyl, morpholinyl, hexahydropyrimidinyl, piperazinyl,
[0176] The heterocycloalkyl group may be monovalent, divalent, trivalent or tetravalent.
[0177] "Alkenyl" refers to a substituted or unsubstituted straight chain or branched unsaturated hydrocarbon group having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms. Examples of alkenyl groups include but are not limited to vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2-methyl-1-butenyl, 2-methyl-2 ... -methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene and 1,4-hexadiene, etc.; the alkenyl group can be monovalent, divalent, trivalent or tetravalent.
[0178] "Alkynyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon triple bonds, with a backbone comprising 2 to 10 carbon atoms, including but not limited to 2 to 6 carbon atoms in the backbone, 2 to 4 carbon atoms in the backbone, examples of alkynyl groups include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 5-pentynyl, 6-pentynyl, 7-pentynyl, 8-pentynyl, 9-pentynyl, 10-pentynyl, 11-pentynyl, 12-pentynyl, 13-pentynyl, 14-pentynyl, 15-pentynyl, 16-pentynyl, 17-pentynyl, 18-pentynyl, 19-pentynyl, 20-pentynyl, 21-pentynyl, 22-pentynyl, 23-pentynyl, 24-pentynyl, 25-pentynyl, 26-pentynyl, 27-pentynyl, 28-pentynyl, 29-pentynyl, 30-pentynyl, 31-pentynyl, 32-pentynyl, 33-pentynyl, 34-pentynyl, 35-pentynyl, 36-pentynyl, 37-pentynyl, 38-pentynyl, 39-pentynyl, 40-pentynyl, 41-pentynyl, 42-pentynyl, 43-pentynyl, 44-pentynyl, 45-pentynyl, 46-pentynyl, 47-pentynyl, 48-pentynyl 1-methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl and the like; the alkynyl group may be monovalent, divalent, trivalent or tetravalent.
[0179] "Alkoxy" refers to substituted or unsubstituted -O-alkyl. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.
[0180] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted aromatic or non-aromatic ring, which can be a 3-8-membered monocyclic ring, a 4-12-membered bicyclic ring, a 10-15-membered tricyclic ring, or a 12-18-membered quaternary system. The carbocyclyl can be attached to an aromatic ring or a non-aromatic ring, and the ring can be optionally a monocyclic ring, a cyclic ring, a bridged ring, or a spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, benzene ring, naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent or tetravalent.
[0181] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring, a 10-15 membered tricyclic ring, or a 12-18 membered quaternary system, and contains 1 or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O, S or Se. The C, N, S or Se selectively substituted in the heterocyclyl ring can be oxidized to various oxidation states. The heterocyclic group can be connected to a heteroatom or a carbon atom, and can be connected to an aromatic ring or a non-aromatic ring. The heterocyclic group is optionally a monocyclic, bridged, fused or spirocyclic ring. Non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxhexacyclyl, azepanyl, pyridyl, furanyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonanyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl,
[0182] "Heterocyclyl" or "heterocycle" may be monovalent, divalent, trivalent or tetravalent.
[0183] "Spiro" or "spirocyclyl" refers to a polycyclic group in which substituted or unsubstituted monocyclic rings share one atom (called spiro atom), and the number of ring atoms in the spiro system includes but is not limited to 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds, and optionally may contain 0 to 5 selected from N, O or S (=O) n (n is 0, 1 or 2).
[0184]
[0185] "Spirocycle" or "spirocyclyl" can be monovalent, divalent, trivalent or tetravalent.
[0186] "Parallel ring" or "parallel ring group" refers to a polycyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds and may be substituted or unsubstituted, and each ring in the parallel ring system may contain 0 to 5 heteroatoms or groups containing heteroatoms (including but not limited to selected from N, S (=O) n or O, n is 0, 1 or 2). The number of ring atoms in the ring system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, 5 to 10. Non-limiting examples include:
[0187]
[0188] "Bicyclic" or "bicyclic group" can be monovalent, divalent, trivalent or tetravalent.
[0189] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing any two atoms that are not directly connected, and may contain 0 or more double bonds. Any ring in the bridged ring system may contain 0 to 5 groups selected from heteroatoms or heteroatom-containing groups (including but not limited to N, S(=O)n or O, where n is 0, 1, 2). The number of ring atoms includes but is not limited to 5 to 20, 5 to 14, 5 to 12 or 5 to 10. Non-limiting examples include
[0190]
[0191] cube
[0192] A "bridged ring" or "bridged ring group" may be monovalent, divalent, trivalent or tetravalent.
[0193] "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" refers to a "spirocycle" wherein the ring system consists of only carbon atoms.
[0194] "Carbocyclic", "cyclic carbocyclyl", "carbocyclyl" or "carbocyclyl" refers to a "cyclic" ring system consisting of only carbon atoms.
[0195] "Carbobridged ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" refers to a "bridged ring" wherein the ring system consists of only carbon atoms.
[0196] "Heteromonocycle", "monocyclic heterocyclyl" or "heteromonocyclyl" refers to a monocyclic ring system of "heterocyclyl" or "heterocycle",
[0197] "Heterocyclic ring", "heterocyclic group", "cycloheterocyclyl" or "cycloheterocyclyl" refers to a "cyclo" containing a heteroatom.
[0198] "Heterospirocycle", "heterospirocyclyl", "spiroheterocyclyl" or "spiroheterocyclyl" refers to a "spirocycle" containing a heteroatom.
[0199] "Heterobridged ring", "heterobridged ring group", "bridged ring heterocyclyl" or "bridged heterocyclyl" refers to a "bridged ring" containing a heteroatom.
[0200] "Aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or a fused ring, wherein the number of ring atoms in the aromatic ring includes, but is not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbon ring, wherein the ring connected to the parent structure is the aryl ring, non-limiting examples of which include benzene ring, naphthalene ring, "Aryl" or "aromatic ring" can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.
[0201] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group, and contains 1 to 5 selected heteroatoms or groups containing heteroatoms (including but not limited to N, O, S(=O)n or Se(=O)n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring includes but is not limited to 5 to 15, 5 to 10 or 5 to 6. The atoms C, N, and S on the ring are optionally oxidized (i.e., C(=O), NO, S(=O)n, Se(=O)n, n is 1, 2). Non-limiting examples of heteroaryl include but are not limited to pyridyl, furanyl, thienyl, selenophenyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazolyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, pyridonyl, and the like. The heteroaryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples include
[0202]
[0203] The heteroaryl groups appearing in this article have the same definition as this definition. The heteroaryl group can be monovalent, divalent, trivalent or tetravalent. When it is divalent, trivalent or tetravalent, the attachment site is located on the aromatic ring.
[0204] "Substituted" or "substituted" means substituted by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2) m -C(=O)-R a、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -Alkenyl-R a , OR d or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silane or -NR b R c etc., where R b With R c is independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, R b With R c Can form a five- or six-membered cycloalkyl or heterocyclic group, R a With R d Each is independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged, spiro or paracyclic groups.
[0205] "1 to X substituents selected from..." means substituted by 1, 2, 3...X substituents selected from..., where X is selected from any integer between 1 and 10. For example, "1 to 4 R k "Substituted" means replaced by 1, 2, 3 or 4 R k For example, "1 to 5 substituents selected from..." means substituted by 1, 2, 3, 4 or 5 substituents selected from..." For example, "the heterobridged ring is optionally substituted by 1 to 4 substituents selected from H or F" means that the heterobridged ring is optionally substituted by 1, 2, 3 or 4 substituents selected from H or F.
[0206] The XY-membered ring (X, Y are integers, and 3≤X<Y, X<Y≤20 is selected from any integer between 4 and 20) includes X, X+1, X+2, X+3, X+4...Y-membered rings. The ring includes a heterocyclic ring, a carbocyclic ring, an aromatic ring, an aryl group, a heteroaryl group, a cycloalkyl group, a heteromonocyclic ring, a heterocyclic ring, a heterospirocyclic ring or a heterobridged ring. For example, "4-7-membered heteromonocyclic ring" refers to a 4-membered, 5-membered, 6-membered or 7-membered heteromonocyclic ring, and "5-10-membered heterocyclic ring" refers to a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered heterocyclic ring.
[0207] C x-yCarbocycles (including aryl, cycloalkyl, monocyclic carbocycle, spirocyclic carbocycle, fused carbocycle or bridged carbocycle) include C x , C x+1 , C x+2 , C x+3 , C x+4 …C y A ring of 1-membered ring (x is an integer, and 3≤x<y, y is selected from any integer between 4 and 20), for example. 3-6 "Cycloalkyl" means C3, C4, C5 or C6 cycloalkyl;
[0208] When a group has one or more connectable sites, any one or more sites of the group can be connected to other groups through chemical bonds. When the chemical bond connection is non-positional and there are hydrogen atoms at the connectable sites, when the chemical bonds are connected, the number of H atoms at the site will decrease with the number of connected chemical bonds and become a group with the corresponding valence. For example It means that any connectable site on the piperidine group can be connected to other groups through one chemical bond, including at least These four connection methods, even if the H atom is drawn on -N-, Also included For example Indicates that the R group on the piperidinyl group can be located on C, can be located on N, and at least includes
[0209] When the listed linking groups do not specify their connection direction, their connection directions include connection from left to right and from right to left in reading order, for example, when ALB, L is selected from -MW-, it includes AMWB and AWMB.
[0210] "Optional" or "optionally" means that the event or circumstance described later may but need not occur, and the description includes situations where the event or circumstance occurs or does not occur. For example, "alkyl optionally substituted with F" means that alkyl may but need not be substituted with F, and the description includes situations where alkyl is substituted with F and situations where alkyl is not substituted with F.
[0211] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, and the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.
[0212] "Pharmaceutical composition" refers to a mixture of one or more compounds described in the present invention, or their stereoisomers, tautomers or pharmaceutically acceptable salts and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.
[0213] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.
[0214] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
[0215] "Prodrug" refers to a compound of the present invention that can be converted into a biologically active compound through in vivo metabolism. The prodrug of the present invention is prepared by modifying the amino or carboxyl group in the compound of the present invention, and the modification can be removed by conventional operations or in vivo to obtain the parent compound. When the prodrug of the present invention is administered to a mammalian subject, the prodrug is cleaved to form a free amino or carboxyl group.
[0216] "Co-crystal" refers to a crystal formed by the active pharmaceutical ingredient (API) and the co-crystal former (CCF) under the action of hydrogen bonds or other non-covalent bonds, in which the pure state of API and CCF are solid at room temperature and there is a fixed stoichiometric ratio between the components. Co-crystal is a multi-component crystal, including binary eutectics formed between two neutral solids and multi-component eutectics formed between neutral solids and salts or solvates.
[0217] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.
[0218] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.
[0219] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomerism and amide-imino alcohol isomerism. DETAILED DESCRIPTION
[0220] The following embodiments illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.
[0221] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were measured in 10 -6The unit of (ppm) is given. NMR measurements were performed using a (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic spectrometer, the measurement solvents were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS);
[0222] MS was measured using (Agilent 6120B (ESI) and Agilent 6120B (APCI));
[0223] HPLC determination was performed using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100×4.6 mm, 3.5 μM);
[0224] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) uses a specification of 0.15mm-0.20mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm;
[0225] Column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier;
[0226] In order to accomplish the purpose of the present invention, the compounds used in the reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources, including Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai McLean Biochemical Technology Co., Ltd., Sigma-Aldrich, Alfa Aesar (China) Chemical Co., Ltd., TCI (Shanghai) Chemical Industry Development Co., Ltd., Anage Chemical, Shanghai Titan Technology Co., Ltd., Kelon Chemical, Bailingwei Technology Co., Ltd., etc.
[0227] THF: Tetrahydrofuran; DMF: N,N-dimethylformamide; DIPEA: N,N-diisopropylethylamine; HATU: CAS148893-10-1
[0228] Example 1: Preparation of Compound 1
[0229]
[0230] Step 1: Preparation of 1b
[0231] N-bromosuccinimide (6.13 g, 34.42 mmol) was added to a solution of 1a (4.50 g, 28.45 mmol) in acetic acid (100 mL) and stirred at room temperature for 2 h. Water (100 mL) and ethyl acetate (100 mL x 2) were added for extraction. The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 83:17) to obtain 1b (3.70 g, yield 55%).
[0232] LCMS m / z=237.0[M+1] +
[0233] Step 2: Preparation of 1c
[0234] 1b (3.70 g, 15.61 mmol) was dissolved in sodium hydroxide aqueous solution (250 mL, 2N) and reacted at 100°C for 16 h. The pH was adjusted to 3-4 with 2N hydrochloric acid at 0°C and extracted with ethyl acetate (250 mL x 3). The organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 80:20) to obtain 1c (1.57 g, yield 39%).
[0235] LCMS m / z=256.0[M+1] +
[0236] Step 3: Preparation of 1d
[0237] 1c (4.70 g, 18.35 mmol) was dissolved in N,N-dimethylformamide (80 mL), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazole-1-yl) urea hexafluorophosphate (8.37 g, 22.02 mmol), N,N-diisopropylethylamine (11.86 g, 91.75 mmol) and ethylamine hydrochloride (4.49 g, 55.05 mmol) were added, and the mixture was reacted at room temperature for 16 h. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL x 3), and the organic phases were combined. The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: tetrahydrofuran (v:v) = 83:17) to obtain 1d (4.50 g, yield 87%).
[0238] LCMS m / z=283.1[M+1] +
[0239] Step 4: Preparation of 1e
[0240] 1d (1.40 g, 4.94 mmol) was dissolved in tetrahydrofuran (50 mL), triphosgene (0.59 g, 1.98 mmol) was added, and the mixture was reacted at 60 °C for 4 h. After cooling to room temperature, water (40 mL) was added, and the mixture was extracted with ethyl acetate (40 mL x 2). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (dichloromethane: methanol (v:v) = 95:5) to obtain 1e (1.50 g, yield 98%).
[0241] LCMS m / z=309.0[M+1] +
[0242] Step 5: Preparation of 1f
[0243] 1e (1.50 g, 4.85 mmol) was added to phosphorus oxychloride (70 mL) and reacted at 95 ° C for 16 h under nitrogen protection. Cooled to room temperature, concentrated under reduced pressure, diluted with dichloromethane (80 mL), and adjusted to pH 8-9 with saturated sodium bicarbonate aqueous solution. Layered, the aqueous phase was extracted with dichloromethane (80 mL x 2), and the organic phases were combined. The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: tetrahydrofuran (v:v) = 92:8) to obtain 1f (489 mg, yield 31%).
[0244] LCMS m / z=327.1[M+H] +
[0245] Step 6: Preparation of 1g
[0246] 1f (315 mg, 0.96 mmol) was dissolved in dimethyl sulfoxide (10 mL), 5-fluoroisoindoline hydrochloride (0.22 g, 1.25 mmol) and N,N-diisopropylethylamine (0.50 g, 3.84 mmol) were added, and the mixture was reacted at 90 °C for 16 h under nitrogen protection. After cooling to room temperature, water (20 mL) was added, and ethyl acetate (20 mL) was used for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 91:9) to obtain 1g (400 mg, yield 97%).
[0247] Step 7: 1h preparation
[0248] 1g (400mg, 0.93mmol), bistriphenylphosphine palladium dichloride (65mg, 0.09mmol) and tributyl (1-ethoxyethylene) tin (0.43g, 1.19mmol) were added to dry 1,4-dioxane (mL) and reacted at 100℃ for 16h under nitrogen atmosphere. The reaction solution was cooled to 50℃, and aqueous hydrochloric acid solution (3mL, 1N) was added and stirred for 1h. After cooling to room temperature, saturated aqueous potassium fluoride solution (8mL) was added and stirred for 30min. Filter, add water (30mL) to the filtrate, and extract with ethyl acetate (40mL). The organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: tetrahydrofuran (v:v) = 90:10) to obtain 1h (90mg, yield 25%).
[0249] LCMS m / z=392.2[M+H] +
[0250] Step 8: Preparation of 1i
[0251] Sodium borohydride (27 mg, 0.72 mmol) was added to a solution of 1h (250 mg, 0.64 mmol) in dichloromethane (7 mL) and methanol (7 mL) at 0°C and reacted at room temperature for 2 h. Water (10 mL) was added and extracted with ethyl acetate (30 mL x 2), and the organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 1i (250 mg, yield 99%).
[0252] LCMS m / z=394.4[M+H] +
[0253] Step 9: Preparation of 1j
[0254] Boron tribromide (260 mg, 0.96 mmol) was added dropwise to a solution of 1i (250 mg, 0.64 mmol) in dichloromethane (7 mL) and reacted at room temperature for 2 h. The reaction system was directly used in the next step.
[0255] Step 10: Preparation of 1k
[0256] At 0°C, the reaction solution from the previous step was added dropwise to a solution of ammonia (10 mL, 28%) in dichloromethane (10 mL), and the mixture was reacted at room temperature for 16 h. Water (10 mL) was added, and the mixture was extracted with dichloromethane (20 mL x 2), and the organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (dichloromethane: methanol (v:v) = 85:15) to obtain 1k (120 mg, two-step yield 48%).
[0257] LCMS m / z=393.4[M+H]+
[0258] Step 11: Preparation of 1L
[0259] Add 6-chloro-3-fluoropyridine-2-carboxylic acid methyl ester (71 mg, 0.37 mmol) and N,N-diisopropylethylamine (160 mg, 1.24 mmol) to dimethyl sulfoxide (3 mL) of 1k (120 mg, 0.31 mmol) and react at 100°C for 16 h. Cool to room temperature, add water (20 mL), and extract with ethyl acetate (20 mL x 2). Combine the organic phases, wash with saturated brine (20 mL x 3), dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure to obtain a crude product, which is separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 20:80) to obtain 1l (120 mg, yield 70%).
[0260] Step 12: Preparation of compound 1
[0261] Aqueous hydroxide solution (2N, 1.80mmol, 0.9mL) was added to a solution of 1l (100mg, 0.18mmol) in methanol (5mL) and tetrahydrofuran (5mL), and the mixture was reacted at 50℃ for 1h. The mixture was concentrated under reduced pressure, and the pH of the residue was adjusted to 6-7 with 1N aqueous hydrochloric acid at 0℃, and extracted with ethyl acetate (10mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by preparative liquid chromatography (instrument: waters 2767 preparative liquid chromatography; chromatographic column: SunFire@Prep C18 (19mm×150mm); mobile phase composition: mobile phase A: acetonitrile mobile phase B: water (containing 0.05% trifluoroacetic acid)) to obtain compound 1 (15mg, yield 15%).
[0262] LCMS m / z=548.2[M+H] +
[0263] 1 H NMR(400MHz,DMSO-d6)δ12.79(s,1H),8.64-8.49(m,1H),7.76(s,1H),7.48-7.38(m,1H),7.32-7.23(m,2H),7.19-7.03(m,2H),5.70- 5.49(m,1H),5.12-4.89(m,4H),4.28-4.08(m,2H),3.19-3.07(m,1H),2.93-2.74(m,3H),2.07-1.93(m,2H),1.62(d,3H),1.44(t,3H).
[0264] Example 2: Preparation of Compound 2
[0265]
[0266] Compound 2 was obtained using 1i and 4,4-difluoropiperidine as starting materials by referring to the synthesis method of Example 1.
[0267] LCMS m / z=532.3[M+H] +
[0268] 1 H NMR (400MHz, DMSO-d6) δ12.79(s,1H),8.71-8.51(m,1H),7.80(s,1H),7.33(d,1H),7.14(d,1H),5.60-5.42(m,1H),4.13-4.05( m,2H),3.40-3.30(m,4H),3.21-3.07(m,1H),2.98-2.78(m,3H),2.28-2.14(m,4H),2.08-1.95(m,2H),1.62(d,3H),1.27(t,3H).
[0269] Example 3: Preparation of Compound 3
[0270]
[0271] Step 1: Preparation of 3b
[0272] 3a (612 mg, 3.40 mmol) was dissolved in dichloromethane (50 mL), phosphorus pentachloride (707 mg, 3.40 mmol) was added, and the mixture was reacted at 45°C for 30 min. 1d (800 mg, 2.83 mmol) was added, and the mixture was reacted at 45°C overnight. Cooled to room temperature, water (100 mL) was added, and dichloromethane (100 mL x 2) was used for extraction. The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 90:10) to obtain 3b (1.00 g, yield 69%).
[0273] LCMS m / z=427.0[M+H] +
[0274] Compound 3 was obtained using 3b as the starting material by referring to the synthesis method of Example 1.
[0275] LCMS m / z=547.2[M+H] + .
[0276] 1H NMR (400MHz, DMSO-d6) δ12.76(s,1H),8.72-8.58(m,1H),7.86(s,1H),7.38(d,1H),7.23(d,1H),5.62-5.43(m,1H),4. 22-4.08(m,2H),3.24-3.13(m,1H),3.08-2.85(m,3H),2.73-2.56(m,6H),2.13-1.98(m,2H),1.66(d,3H),1.25(t,3H).
[0277] Example 4: Preparation of Compound 4
[0278]
[0279] Step 1: Preparation of 4a
[0280] 3f (240 mg, 0.53 mmol) and methyl 2-aminobenzoate (160 mg, 1.06 mmol) were dissolved in N,N-dimethylformamide (10 mL) and reacted at 80 °C for 16 h. After cooling to room temperature, water (20 mL) was added and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine (20 mL x 3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 92:8) to obtain 4a (170 mg, yield 61%).
[0281] LCMS m / z=526.4[M+H] +
[0282] Step 2: Preparation of compound 4
[0283] Aqueous hydroxide solution (2N, 18.94mmol, 9.47mL) was added to a solution of 4a (160mg, 0.30mmol) in methanol (5mL) and tetrahydrofuran (5mL), and the mixture was reacted at 50°C for 8h. The mixture was concentrated under reduced pressure, and the pH of the residue was adjusted to 6-7 with 1N aqueous hydrochloric acid at 0°C, and extracted with ethyl acetate (10mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by preparative liquid chromatography (instrument: waters2767 preparative liquid chromatography; chromatographic column: SunFire@Prep C18 (19mm×150mm); mobile phase composition: mobile phase A: acetonitrile mobile phase B: water (containing 0.05% trifluoroacetic acid)) to obtain compound 4 (15mg, yield 10%).
[0284] LCMS m / z=512.3[M+H] +
[0285] 1 H NMR(400MHz,DMSO-d6)δ12.46(s,1H),8.69-8.40(m,1H),7.84(s,1H),7.75(dd,1H),7.28-7.15(m,1H),6.62(d,1H),6.50-6.42(m,1H),5. 73-5.51(m,1H),4.23-4.08(m,2H),3.26-3.13(m,1H),3.08-2.81(m, 3H),2.73-2.57(m,6H),2.11-1.94(m,2H),1.63(d,3H),1.25(t,3H).
[0286] Example 5: Preparation of Compound 5-A and Compound 5-B
[0287]
[0288] Step 1: Preparation of compound 5a
[0289] 3-Fluorobicyclo[1.1.1]pentane-1-carboxylic acid (92 mg, 0.71 mmol) was dissolved in dichloromethane (30 mL), phosphorus pentachloride (147 mg, 0.71 mmol) was added, and the mixture was reacted at 45°C for 30 min. 1d (201 mg, 0.71 mmol) was added, and the mixture was reacted at 45°C for 16 h. The mixture was cooled to room temperature, and water (80 mL) was added. The mixture was extracted with dichloromethane (50 mL x 2). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated by column chromatography (petroleum ether: ethyl acetate (v:v) = 90:10) to obtain 3b (185 mg, yield 69%).
[0290] LCMS m / z=377.3[M+H] +
[0291] Step 2: Preparation of compound 5b
[0292] 5a (711 mg, 1.88 mmol), bistriphenylphosphine palladium dichloride (132 mg, 0.19 mmol) and tributyl (1-ethoxyethylene) tin (869 mg, 2.41 mmol) were added to 1,4-dioxane (10 mL) and reacted at 100 ° C for 16 h under nitrogen atmosphere. Aqueous hydrochloric acid solution (5 mL, 1N) was added at 50 ° C and reacted for 1 h. Saturated aqueous potassium fluoride solution (10 mL) was added at room temperature and stirred for 30 min. Filter, add water (20 mL), and extract with ethyl acetate (40 mL). The organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v: v) = 90: 10) to obtain 5b (350 mg, yield 55%).
[0293] LCMS m / z=341.1[M+H] +
[0294] Step 3: Preparation of compound 5c
[0295] Sodium borohydride (245 mg, 6.48 mmol) was added to a solution of 5b (550 mg, 1.62 mmol) in methanol (20 mL) at 0°C and reacted at room temperature for 2 h. Water (3 mL) was added at 0°C and concentrated under reduced pressure. Water (20 mL) was added to the residue and extracted with ethyl acetate (30 mL x 2). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 5c (529 mg, yield 96%).
[0296] LCMS m / z=343.1[M+H] +
[0297] Step 4: Preparation of compound 5d
[0298] Phosphorus tribromide (475 mg, 1.75 mmol) was added dropwise to a solution of 5c (402 mg, 1.17 mmol) in dichloromethane (10 mL), and the mixture was reacted at room temperature for 2 h. The mixture was concentrated under reduced pressure, and ethyl acetate (20 mL) and ice water (20 mL) were added to the residue. The layers were separated, and the aqueous phase was extracted with ethyl acetate (20 mL). The organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 5d (470 mg, crude product).
[0299] Step 5: Preparation of compound 5e
[0300] Potassium phthalimide (258 mg, 1.39 mmol) and potassium iodide (96 mg, 0.58 mmol) were added to a solution of 5d (470 mg, crude product) in N,N-dimethylformamide (5 mL) and reacted at 70°C for 16 h. At room temperature, water (50 mL) and ethyl acetate (20 mL x 2) were added for extraction, and the organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate (v:v) = 84:16) to obtain 5e (279 mg, two-step yield: 50%)
[0301] Step 6: Preparation of compound 5f
[0302] Hydrazine hydrate (1 mL, 80%) was added to a solution of 5e (279 mg, 0.59 mmol) in ethanol (10 mL) and reacted at room temperature for 15 h. The mixture was filtered, the filter cake was washed with ethyl acetate (10 mL x 3), and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was slurried with ethyl acetate (10 mL), filtered, the filter cake was washed with ethyl acetate (10 mL x 3), and the filtrate was concentrated under reduced pressure to obtain compound 5f (200 mg, crude product).
[0303] LCMS m / z=342.2[M+H] +
[0304] Step 7: Preparation of compound 5g
[0305] Add 5-chloro-3-fluoropyridine-2-carboxylic acid methyl ester (134 mg, 0.71 mmol) and N,N-diisopropylethylamine (305 mg, 2.36 mmol) to a solution of 5f (200 mg, crude product) in dimethyl sulfoxide (5 mL) and react at 100 ° C for 15 h. Cool to room temperature, add water (50 mL), and extract with ethyl acetate (20 mL x 2). Combine the organic phases, wash the organic phase with saturated brine (40 mL), dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure to obtain a crude product, which is separated and purified by column chromatography (petroleum ether: ethyl acetate (v: v) = 82:18) to obtain 5g (247 mg, two-step yield 82%).
[0306] LCMS m / z=511.2[M+H] +
[0307] Step 8: Preparation of compound 5
[0308] Aqueous hydroxide solution (2N, 4.00mmol, 2.0mL) was added to a solution of 5g (200mg, 0.39mmol) of methanol (4mL) and tetrahydrofuran (4mL), and the mixture was reacted at room temperature for 1h. The residue was concentrated under reduced pressure, and the pH was adjusted to 5-7 with 1N aqueous hydrochloric acid at 0°C, and extracted with ethyl acetate (20mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by slurrying (petroleum ether: ethyl acetate (v:v) = 20 / 1, 15mL) to obtain compound 5 (164mg, yield 84%).
[0309] LCMS m / z=497.2[M+H] +
[0310] Step 5: Preparation of Compound 5-A and Compound 5-B
[0311]
[0312] Compound 5 was purified by SFC on Chiral OJ column (instrument and preparative column: Waters 150Prep-SFC, preparative column model: Chiral OJ column. Preparation method: After compound 5 was dissolved, it was filtered with a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for MeOH (0.1% NH3·H2O). Gradient elution method: 35% mobile phase B isogradient elution (flow rate: 100mL / min; elution time 5min)) to obtain compound 5-A (compound 5-A is one of the structures of compound 5-1 and compound 5-2) and compound 5-B (compound 5-B is one of the structures of compound 5-1 and compound 5-2).
[0313] Analytical method (instrument and preparation column: SHIMADZU LC-30AD, analytical column model: Chiral OJ column. Mobile phase system: A for CO2; B for 0.05% DEA in MeOH, column temperature: 35°C, flow rate: 3.0 mL / min. Retention time T = 1.574 min is compound 5-A (compound 5-A is one of the structures of compound 5-1 and compound 5-2). Retention time T = 1.852 min is compound 5-B (compound 5-B is one of the structures of compound 5-1 and compound 5-2).
[0314] Compound 5-A:
[0315] LCMS m / z=497.2[M+H] + .
[0316] 1 H NMR(400MHz, CDCl3)δ8.53(d,1H),8.00(s,1H),7.14(d,1H),7.04(d,1H),5.68-5.51(m,1H),4.20(q,2H ),3.23-3.10(m,1H),3.05-2.86(m,3H),2.77-2.62(m,6H),2.19-2.03(m,2H),1.70(d,3H),1.36(t,3H).
[0317] Compound 5-B:
[0318] LCMS m / z=497.2[M+H] + .
[0319] 1 H NMR (400MHz, CDCl3) δ10.43(s,1H),8.53(d,1H),8.00(s,1H),7.14(d,1H),7.04(d,1H),5.68-5.51(m,1H),4.2 0(q,2H),3.23-3.11(m,1H),3.05-2.86(m,3H),2.77-2.62(m,6H),2.17-2.05(m,2H),1.70(d,3H),1.36(t,3H).
[0320] Example 6: Preparation of Compound 6-A and Compound 6-B
[0321]
[0322] Compound 1 was purified by SFC on AS column (instrument and preparation column: SFC Prep 150AP, preparation column model: Daicel IG-H (19mm*250mm). Preparation method: Compound 1 was dissolved in methanol and filtered with a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for EtOH. Gradient elution method: 25% mobile phase B isocratic elution (flow rate: 40mL / min;)), retention time T=5.2min for compound 6-A; retention time T=5.5min for compound 6-B) to obtain compound 6-A (compound 6-A is one of the structures of compound 6-1 and compound 6-2) and compound 6-B (compound 6-B is one of the structures of compound 6-1 and compound 6-2).
[0323] Compound 6-A (Compound 6-A is one of the structures of Compound 6-1 and Compound 6-2):
[0324] LCMS m / z=548.2[M+H] + .
[0325] 1 H NMR(400MHz,DMSO-d6)δ9.04-8.81(m,1H),7.74(s,1H),7.48-7.38(m,1H),7.32-7.23(m,1H),7.18-7.08(m,2H),7.02-6.89(m,1H),5.7 0-5.49(m,1H),5.12-4.91(m,4H),4.27-4.06(m,2H),3.19-3.07(m,1H),2.96-2.72(m,3H),2.07-1.93(m,2H),1.59(d,3H),1.44(t,3H).
[0326] Compound 6-B (Compound 6-B is one of the structures of Compound 6-1 and Compound 6-2):
[0327] LCMS m / z=548.2[M+H] + .
[0328] 1 H NMR(400MHz,DMSO-d6)δ9.07-8.75(m,1H),7.74(s,1H),7.47-7.39(m,1H),7.32-7.23(m,1H),7.18-7.08(m,2H),7.02-6.89(m,1H),5.7 2-5.48(m,1H),5.12-4.91(m,4H),4.27-4.06(m,2H),3.19-3.07(m,1H),2.96-2.72(m,3H),2.07-1.93(m,2H),1.59(d,3H),1.44(t,3H).
[0329] Biological test cases
[0330] MDA-MB-453 cell proliferation inhibition experiment
[0331] Method 1: MDA-MB-453 cells (ATCC, Cat#30-2008) were cultured in L-15 medium (with 10% FBS and 1% double antibody) under CO2-free conditions. When the cell confluence reached 80%-90%, the cells were collected and plated. The medium was discarded, and trypsin (Gibco, Cat#15400-054) was added to digest after rinsing with 1×PBS. When the cells became round and began to fall off, the medium was added to terminate the digestion. The cells were blown down and transferred to a sterile centrifuge tube, centrifuged at 1000rpm for 3 minutes, and the supernatant was removed after centrifugation. The centrifuge tube was added with medium to resuspend the cells and counted. According to the counting results, the cell suspension was adjusted to an appropriate concentration and added to a 96-well cell culture plate (Corning, Cat#3903). The compound was dissolved in DMSO to 10mM and stored for use. The compound mother solution was diluted in sequence during the experiment. The compound was added 24 hours after plating and cultured for 4 days at 37°C and CO2-free conditions. After the incubation, CELL VIABILITY reagent (Promega, Cat#G7573) was added to each well and incubated at room temperature for 10 minutes. After the incubation, the well was gently shaken 5 times, and then the chemiluminescence reading was detected using a BMG microplate reader (PHERAstar FSX). According to the formula [(1–(RLU compound –RLU blank ) / (RLU control –RLU blank )) × 100%] to calculate the cell proliferation inhibition rate. The IC was obtained by four-parameter nonlinear fitting using GraphPad Prism software. 50 value.
[0332] Method 2 (MTS assay): MDA-MB-453 cells (ATCC, Cat#HTB-131) were cultured with L-15 medium (added with 10% FBS), and cells in the logarithmic growth phase were used for plating. The culture medium was discarded, and trypsin (Gibco, Cat#15400-054) was added for digestion after rinsing with 1×PBS. When the cells became round and began to fall off, the culture medium was added to terminate the digestion, and the cells were blown down and transferred to a sterile centrifuge tube, centrifuged at 1000rpm for 3 minutes, and the supernatant was discarded. The culture medium was added to the centrifuge tube to resuspend the cells and count them. According to the counting results, the cell suspension was adjusted to an appropriate concentration and added to a 96-well cell culture plate (Greiner, Cat#655090). The compound was dissolved in DMSO to 10mM and stored for later use. The compound mother solution was diluted in sequence during the experiment. The compound was added 24 hours after plating, and the culture was continued for 7 days at 37°C and 5% CO2. After incubation, add CellTiter AQueous One Solution Reagent (Promega, Cat#G3582), the cell culture plate was placed in an incubator at 37°C, 0% CO2 for 4 hours, and then the OD490nm was detected using a SpectraMax 340PC microplate reader. The cell proliferation inhibition rate was calculated according to the formula [1-(RLU compound-RLU blank control) / (RLU solvent control-RLU blank control)]×100%. GraphPad Prism software was used to draw the inhibition curve and calculate the IC 50 Values are shown in Table 1.
[0333] Table 1 Inhibition of proliferation of MDA-MB-453 cells by compounds
[0334] Serial number Test Method Compound No. <![CDATA[IC 50 (nM)]]> 1 Method 2 Compound 1 <200 2 Method 2 Compound 5-B <200
[0335] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good inhibitory activity against MDA-MB-453 cells.
[0336] PI3K enzyme activity test method
[0337] Use DMSO to dilute the compound in a series in the 384PP Plate compound dilution plate, and use Echo to transfer 0.1 μL of the compound to a 384 reaction microplate (Optiplate 384), ensuring that the final DMSO concentration is 1% (duplicate wells). Add 5 μL of 2X enzyme solution (PIK3CA, PIK3CA[H1047R]) to each well of the 384 reaction microplate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes. Add 5 μL of 2X ATP and PIP2:3PS solution to each well, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 180 minutes. Add 5 μL of ADP-Glo Reagent to each well, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes. Add 10 μL of ADP-Glo Detection buffer to each well, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes. The RLU (Relative luminescence unit) signal was read on a BMG (PHERAstar FSX) microplate reader. The wells containing 1% DMSO and enzyme were used as High Control, and the wells containing 1% DMSO and buffer were used as Low Control. The inhibition percentage of the compound-treated wells was standardized between High Control and Low Control (%inhibition = (RLU High Control-RLU compound reading) / (RLU High Control-RLU Low Control)*100). Then the four-parameter IC was fitted by XLfit5.5.0 50 Curve and analysis, IC 50 is the compound concentration corresponding to 50% inhibition rate, see Table 2.
[0338] Table 2 Inhibitory activity of compounds against PIK3CA[H1047R] enzyme
[0339] Serial number Compound No. <![CDATA[IC 50 (nM)]]> 1 Compound 5-B <200 2 Compound 6-B <50
[0340] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good inhibitory activity against PIK3CA[H1047R] enzyme.
Claims
1. A compound or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, the compound being selected from the compounds represented by general formula (I), in, represents an aromatic ring or a non-aromatic ring; Z is selected from O and S; X 1 Selected from N, CH, NH, NR x1 , CR x2 ; X 2 Selected from CH, NH, NR x1 , CR x2 ; X 3 Selected from C or N, X 3 When selected from C, X 2 Cannot be selected from CH or CR x2 ; W 1 , W 2 , W 3 , W 4 Each independently selected from a bond, O, S, N, NR w1 , CR w2 or CR w3 R w4 , the condition is W 1 , W 2 , W 3 , W 4 At most one of them is selected from a bond. When one of them is selected from a bond and ring C is selected from an aromatic ring, the other three cannot be selected from CR at the same time. w2 ; When C is selected from a 6-membered aromatic ring or a heteroaromatic ring, W 1 , W 2 , W 3 , W 4 Each independently selected from N or CR x2 , and W 1 , W 2 , W 3 , W 4 At most three of them are selected from N; When C is selected from a 5-membered heteroaromatic ring, W 1 Select from key, W 2 , W 3 , W 4 Each independently selected from O, S, N, NR w1 or CR w2 , and W 2 , W 3 , W 4 At least one of the following is selected from CR w2 ; When C is selected from non-aromatic rings, W 1 , W 2 , W 3 , W 4 Each independently selected from a bond, O, S, NR w1 or CR w3 R w4 , and W 1 , W 2 , W 3 , W 4 At most one of them is selected from the key; Y is selected from O, S, NR y1 ; R 1 Selected from -L 1 -R 1a or -L 1 -R 1b ; m is selected from 1, 2, 3, 4; L 1 Each independently selected from a bond, -C≡C-, -C 1-4 Alkylene-, -C(=O)-, -C 0-2 Alkylene-OC 0-2 Alkylene-, -C 0-2 Alkylene-SC 0-2 Alkylene-, -C 0-2 Alkylene-NR L1 -C 0-2 Alkylene-, the alkylene group is optionally substituted by 1 to 4 R k replaced by; R 1a Selected from H, deuterium, halogen, OH, CN, NO 2 NH 2 , COOH, CONH 2 , C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 The alkyl, alkenyl, alkynyl group is optionally substituted by 1 to 4 R k replaced by; R 1b is selected from 4-7 membered heteromonocyclic group, 5-12 membered heterocyclic group, 5-12 membered heterospirocyclic group, 7-10 membered heterobridged ring group, C 3-8 Monocarbocyclic group, C 6-12 Cycloalkyl, C 6-12 Spirocycloalkyl, C 5-12 Benzene-C-cycloalkyl 3-6 Carbocyclic group, benzo 3 to 6 membered heterocyclic group, C 6-10 aryl or 5 to 10 membered heteroaryl, wherein R 1b 1 to 4 selected from R k replaced by; R x1 , R y1 , R w1 , R L1 Each independently selected from H, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -C 0-2 Alkylene-C 3-8 Carbocyclic group, -C 0-2 Alkylene-4 to 8 membered heterocyclic group, wherein the alkyl, alkenyl, alkynyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by; Selected from Ring B is selected from 4-7 membered heteromonocyclic group, 5-12 membered heterocyclic group, 5-12 membered heterospirocyclic group, 7-10 membered heterobridged ring group, C 3-8 Monocarbocyclic group, C 6-12 Cycloalkyl, C 6-12 Spirocycloalkyl, C 5-12 Benzene-C-cycloalkyl 3-6 Carbocyclic group, benzo 3 to 6 membered heterocyclic group, C 6-10 aryl or 5 to 10 membered heteroaryl, the ring B is optionally substituted by 1 to 4 R b replaced by; R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, halogen, OH, CN, NO 2 NH 2 , COOH, CONH 2 , C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 , -C 0-2 Alkylene-C 3-8 Carbocyclic group, -C 0-2 Alkylene-4 to 7 membered heterocyclic group, -C 0-2 Alkylene-C(=O)C 1-4 Alkyl, -C 0-2 Alkylene-C(=O)OC 1-4 Alkyl, -C(=O)-C 3-8 carbocyclyl, -C(=O)-4 to 7 membered heterocyclyl, -C(=O)-CH 2 -C 3-8 Carbocyclic group, -C(=O)-CH 2 -4 to 7 membered heterocyclic group, -C(=O)NHC 1-4 Alkyl, -C(=O)N(C 1-4 alkyl) 2 ,-P(=O)(C 1-4 alkyl) 2 、-S(=O) 1-2 C 1-4 Alkyl, -S(=O) 1-2 NHC 1-4 Alkyl, -S(=O) 1-2 N(C 1-4 alkyl) 2 、-OC 0-2 Alkylene-C 3-8 Carbocyclic group, -OC 0-2 Alkylene-4 to 7 membered heterocyclic group, -SC 0-2 Alkylene-C 3-8 Carbocyclic group, -SC 0-2 Alkylene-4 to 7 membered heterocyclic group, -NHC 0-2 Alkylene-C 3-8 Carbocyclic group, -NHC 0-2 Alkylene-4 to 7 membered heterocyclic group, the CH 2 , alkyl, alkylene, alkenyl, alkynyl, alkoxy, carbocyclic, heterocyclic, optionally 1 to 4 R k replaced by; R 5 , R 6 Each independently selected from H, deuterium, halogen, OH, CN, NO 2 NH 2 , C 1-4 Alkyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 , C 0-2 Alkylene-5 to 8 membered heteroaryl, C 0-2 Alkylene-C 3-8 Carbocyclic group, C 0-2 Alkylene-4 to 8 membered heterocyclic group, wherein the alkyl, alkylene, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replaced by; Alternatively, R 5 , R 6 and the carbon atom to which it is attached directly to form C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl or 3 to 7 membered heterocyclic ring, wherein the cycloalkyl, cycloalkenyl or heterocyclic ring is optionally substituted by 1 to 4 R k replace; R k Each independently selected from deuterium, halogen, =O, CN, OH, NO 2 , COOH, CONH 2 NH 2 , SF 5 、NHC 1-6 Alkyl, N(C 1-6 alkyl) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -C 1-4 Alkylene-C 3-6 Carbon ring, -C 1-4 Alkylene-3 to 7 membered heterocyclic ring, C 3-6 carbocyclic ring, 3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 deuterium, halogen, CN, OH, NH 2 , C 1-6 Alkyl, C 1-6 The alkoxy group is substituted with an alkoxy substituent.
2. The compound according to claim 1 or its stereoisomer, tautomer or pharmaceutically acceptable salt, in, L 1 Each independently selected from a bond, -C≡C-, -C 1-3 Alkylene-, -C(=O)-, wherein the alkylene is optionally substituted by 1 to 4 R k replace; Selected from Selected from represents a single bond or a double bond; C1W 1 , W 2 , W 3 , W 4 Each independently selected from a bond, O, S, NR w1 or CR w3 R w4 , and W 1 , W 2 , W 3 , W 4 At most one of them is selected from a bond, and at most two of them are selected from O, S or NR w1 ; C2W 1 , W 2 , W 3 , W 4 Each independently selected from N or CR w2 , and W 1 , W 2 , W 3 , W 4 At most three of them are selected from N; W in C3 2 , W 3 , W 4 Each independently selected from O, S, N, NR w1 or CR w2 , and W 2 , W 3 , W 4 At least one of them is selected from O, S, N, NR w1 , at least one of the remaining two items is selected from CR w2 ; R k Each independently selected from deuterium, halogen, =O, CN, OH, NO 2 , COOH, CONH 2 NH 2 , SF 5 、NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 , C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -C 1-2 Alkylene-C 3-6 Carbon ring, -C 1-2 Alkylene-3 to 7 membered heterocyclic ring, C 3-6 carbocyclic ring, 3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 deuterium, halogen, CN, OH, NH 2 , C 1-4 Alkyl, C 1-4 The alkoxy group is substituted with an alkoxy substituent.
3. The compound according to claim 2 or its stereoisomer, tautomer or pharmaceutically acceptable salt, in, R 2 , R b , R w2 , R w3 , R w4 , R x2 Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 、NO 2 NHCH 3 、N(CH 3 ) 2 , COOH, CONH 2 or optionally 1 to 4 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -pyrrolidinyl, -O-cyclopropyl, -O-cyclobutyl, -O-pyrrolidinyl, -S-cyclopropyl, -S-cyclobutyl, -NH-cyclopropyl, -NH-cyclobutyl, -OCH 2 - cyclopropyl, imidazole, pyrazole, pyrrole or thiophene; R x1 , R y1 , R w1 Each independently selected from H, deuterium or optionally substituted by 1 to 4 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, -CH 2 -cyclopropyl or -CH 2 - cyclobutyl; Ring B is selected from b One of the following substituted groups: phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl; R 5 , R 6 Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NO 2 NH 2 NHCH 3 、N(CH 3 ) 2 or optionally 1 to 4 R k substituted by one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl; R k Each independently selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH 2 、NO 2 , SF 5 , COOH, CONH 2 NH(CH 3 ), NH(CH 2 CH 3 )、N(CH 3 ) 2 、N(CH 2 CH 3 ) 2 , methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -cyclopentyl, -CH 2 - cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are optionally substituted by 1 to 4 deuterium, halogen, CN, OH, NH 2 , C 1-4 Alkyl, C 1-4 The alkoxy group is substituted with an alkoxy substituent.
4. The compound according to claim 3 or its stereoisomer, tautomer or pharmaceutically acceptable salt, wherein Selected from L 1 Each independently selected from a bond, -C≡C-, methylene, ethylene, -C(=O)-, wherein the methylene and ethylene are optionally substituted by 1 to 3 R k replace; C4W 2 , W 3 Each independently selected from O, S, NR w1 or CR w3 R w4 , and W 2 , W 3 At least one of them is selected from O, S or NR w1 ; C5W 1 , W 4 Each independently selected from O, S, NR w1 or CR w3 R w4 , and W 1 , W 4 At least one of them is selected from O, S or NR w1 ; C6W 3 Each independently selected from O, S, NR w1 ; C7W 2 , W 4 Each independently selected from O, S, NR w1 or CR w3 R w4 , and W 2 , W 4 At least one of them is selected from O, S or NR w1 ; Y is selected from O, S, NH; R 1a Selected from H, deuterium, F, Cl, Br, I, OH, CN, NO 2 NH 2 , COOH, CONH 2 NHCH 3 、N(CH 3 ) 2 or optionally 1 to 3 R k substituted one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio; R 1b Selected from 1 to 3 R k substituted by one of the following groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolane, 1,4-dioxolane, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, thienyl, thiazolyl, furanyl, oxazolyl, isoxazolyl, benzopyrrole, benzothiophene, benzofuran, benzothiazole, benzopyrazole, benzimidazole, quinoline, isoquinoline, pyridopyridine, pyridothiazole, pyridofuran, pyridopyrrole, m is selected from 1.
5. The compound according to claim 4 or its stereoisomer, tautomer or pharmaceutically acceptable salt, Selected from Selected from R 1 Selected from R 1a , R 1b or -C≡CR 1b ; R x2 Selected from H, deuterium, F, Cl, Br, I, OH, CN, NH 2 、NO 2 NHCH 3 、N(CH 3 ) 2 , COOH, CONH 2 or optionally 1 to 3 R k substituted with one of the following groups: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -pyrrolidinyl; R k Each independently selected from R k Each independently selected from deuterium, F, Cl, Br, I, OH, =O, COOH, CN, SF 5 , CHF 2 , CH 2 F. CF 3 , OCHF 2 、OCF 3 , CD 3 , OCD 3 NH 2 NHCH 3 、N(CH 3 ) 2 , CH 2 OH、OCH 2 OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl; Selected from R 2 , R w3 , R x2 Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH 2 、NO 2 NHCH 3 、N(CH 3 ) 2 Or 1, 2, or 3 R k Substituted one of the following groups: methyl, ethyl, propyl, isopropyl.
6. The compound according to claim 1 or its stereoisomer, tautomer or pharmaceutically acceptable salt, wherein the compound is selected from one of the structures shown in Table E-1: Table E-1 7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, preferably, the pharmaceutical composition comprises 1 to 1500 mg of the compound according to any one of claims 1 to 6 or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.
8. Use of the compound according to any one of claims 1 to 6 or its stereoisomers, tautomers or pharmaceutically acceptable salts for preparing a medicament for treating a disease associated with PI3Kα activity or expression.
9. The use according to claim 8, It is characterized in that The disease is selected from tumors, preferably breast cancer.
